Press Releases

2022

NOVEMBER 29

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

2022

OCTOBER 4

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309

Media Coverage

The Dye that Binds: Advances in Tumor Visualization Now Help Surgeons See Cancer in Real-Time

As surgical oncology moves toward increased adoption of minimally invasive techniques and procedures, the ability to locate and see tumors is vital. Once a surgeon loses the ability to visualize directly and use tactile sensation to identify and locate tumors, what can provide that needed layer of confidence?